1. Financial Results Approval

The Board of Directors approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026. The statutory auditors, J.K Jain & Associates, issued an unmodified audit opinion on both sets of results, confirming compliance with Regulation 33 of the SEBI LODR.

2. Thirty-Seventh Annual General Meeting (AGM)

The 37th AGM of the company is scheduled to be held on Thursday, August 20, 2026, through Video Conferencing and Other Audio-Visual Means, pursuant to the Ministry of Corporate Affairs General Circular No. 03/2025.

3. Final Dividend Recommendation & Record Date

The Board recommended a final dividend of ₹10/- (100%) per equity share (face value of ₹10 each) for the financial year 2025-26. This is subject to approval by shareholders at the ensuing AGM.

  • Record Date: Friday, August 7, 2026, has been fixed to determine the shareholders eligible to receive the dividend.
  • Payment: The dividend will be paid within 30 days from the date of the AGM, subject to deduction of TDS.

4. Appointments and Re-appointments

The Board made the following appointments based on the recommendation of the Nomination and Remuneration Committee, all subject to shareholder approval:

  • Mr. Saransh Chaudhary (DIN: 08752105): Appointed as an Additional Director (Whole-Time Director) for a period of 5 years effective May 26, 2026.
  • Dr. Gurminder Singh Bedi (DIN: 11713102): Appointed as an Additional Director (Non-Executive Independent Director) for a period of 5 years effective May 26, 2026. He meets the independence criteria under the Companies Act, 2013 and SEBI LODR.
  • Dr. (Mrs.) Manu Chaudhary (DIN: 00435834): Re-appointed as Joint Managing Director for a period of five years effective October 1, 2026.
  • Dr. (Mrs.) Savita Gupta (DIN: 0009450913): Re-appointed as a Non-Executive Independent Director for a second term of five years effective December 29, 2026.

The company confirmed that none of the appointees have been debarred from holding the office of a director by SEBI or any other authority.

5. Auditor Appointments

On the recommendation of the Audit Committee, the Board appointed:

  • M/s C. L. Bansal & Associates, Cost Accountants as the Cost Auditors for FY 2026-27.
  • M/s Mehra Goel & Co, Chartered Accountants as the Internal Auditors for FY 2026-27.

6. Adoption of New MOA and AOA

The Board approved the adoption of a new Memorandum of Association (MOA) as per Table-A of Schedule I of the Companies Act, 2013 and a new Articles of Association (AOA) as per Table-F of Schedule I of the Companies Act, 2013. These changes are to align the documents with the new Act and are subject to shareholder approval at the AGM. The key change in the MOA is the re-categorization of objects and matters.

7. Trading Window Closure

Pursuant to the Prevention of Insider Trading norms, the trading window for designated persons was closed from April 1, 2026, until 48 hours after the declaration of the financial results (i.e., after May 28, 2026).

8. Standalone Financial Highlights (FY Ended March 31, 2026)

  • Total Revenue: ₹264.35 Crore (Previous Year: ₹182.78 Crore)
  • Total Expenses: ₹202.74 Crore (Previous Year: ₹149.31 Crore)
  • Profit Before Tax (PBT): ₹61.61 Crore (Previous Year: ₹33.47 Crore)
  • Tax Expense: ₹14.11 Crore (Current Tax: ₹14.48 Cr, Deferred Tax: ₹-0.37 Cr)
  • Net Profit: ₹47.49 Crore (Previous Year: ₹25.58 Crore)
  • Earnings Per Share (EPS): ₹35.53 (Basic & Diluted) (Previous Year: ₹19.14)
  • Total Assets: ₹713.22 Crore (Previous Year: ₹876.06 Crore)
  • Total Equity: ₹589.50 Crore (Previous Year: ₹689.63 Crore)

9. Consolidated Financial Highlights (FY Ended March 31, 2026)

  • Total Revenue: ₹782.20 Crore (Previous Year: ₹668.84 Crore)
  • Total Expenses: ₹648.02 Crore (Previous Year: ₹606.93 Crore)
  • Profit Before Tax (PBT): ₹134.16 Crore (Previous Year: ₹71.82 Crore)
  • Tax Expense: ₹31.38 Crore (Current Tax: ₹32.89 Cr, Deferred Tax: ₹-1.52 Cr, Prior Year: ₹-0.00 Cr)
  • Net Profit: ₹102.78 Crore (Previous Year: ₹45.31 Crore)
  • Earnings Per Share (EPS): ₹76.89 (Basic & Diluted) (Previous Year: ₹33.89)
  • Total Assets: ₹863.70 Crore (Previous Year: ₹715.72 Crore)
  • Total Equity: ₹663.75 Crore (Previous Year: ₹560.95 Crore)

10. Subsidiary Information

  • The company has a wholly-owned subsidiary, Venus Pharma GmbH (Germany), and a step-down subsidiary, Venus Pharma Kft (Hungary).
  • The investment in Venus Pharma GmbH remains pending formal share allotment, as it is not mandated under German regulations. Management has engaged a German financial consultancy to advise on the framework for this strategic investment as part of a European operations restructuring.
  • The consolidated results include Venus Pharma GmbH (Assets: ₹24.95 Cr, Revenue: ₹26.84 Cr, Net Profit: ₹3.48 Cr) and Venus Pharma Kft (Assets: ₹0.08 Cr). The audits for these subsidiaries were in process at the reporting date.

11. Large Corporate Status Undertaking

The company submitted an undertaking stating it does not qualify as a 'Large Corporate' as of March 31, 2026, per SEBI circulars, as its outstanding borrowing was Nil.

12. Other Key Notes

  • The company operates in a single reportable segment: "Pharmaceuticals".
  • Previous year figures have been regrouped/reclassified where necessary.
  • The Board meeting commenced at 3:15 PM and concluded at 9:35 PM.